Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis

• Published in: Cancer research (Chicago, Ill.) Ill.), 2001-03, Vol.61 (6), p.2759-2765
• Main Authors: ROTH, Wilfried, ISENMANN, Stefan, NAKAMURA, Mitsutoshi, PLATTEN, Michael, WICK, Wolfgang, KLEIHUES, Paul, BÄHR, Mathias, OHGAKI, Hiroko, ASHKENAZI, Avi, WELLER, Michael
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis - physiology; Biological and medical sciences; Brain Neoplasms - immunology; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Cell Division - physiology; Chemotaxis - physiology; Disease Progression; Fas Ligand Protein; Glioma - immunology; Glioma - metabolism; Glioma - pathology; Humans; Macrophages - immunology; Medical sciences; Membrane Glycoproteins - antagonists & inhibitors; Membrane Glycoproteins - genetics; Mice; Microglia - cytology; Microglia - physiology; Neurology; Rats; Rats, Inbred F344; Receptors, Cell Surface - biosynthesis; Receptors, Cell Surface - immunology; Receptors, Cell Surface - physiology; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 6b; T-Lymphocytes - immunology; Transfection; Tumor Cells, Cultured; Tumors of the nervous system. Phacomatoses
• ISSN: 0008-5472; 1538-7445

Decoy receptor 3 (DcR3) is a newly identified soluble protein that binds to CD95 ligand (CD95L) and inhibits its proapoptotic activity. Here we report that DcR3 is expressed by the majority of long-term and ex vivo malignant glioma cell lines as well as in human glioblastoma in vivo. Expression of DcR3 correlates with the grade of malignancy: 15 of 18 (83%) glioblastomas (WHO grade IV) but none of 11 diffuse astrocytomas (WHO grade II) exhibited DcR3 immunoreactivity. We also demonstrate that human malignant glioma cells engineered to release high amounts of DcR3 into the cell culture supernatant are protected from CD95L-induced apoptotic cell death. In contrast, DcR3 does not confer protection from the death ligand Apo2 ligand (TRAIL). Importantly, ectopic expression of DcR3 resulted in substantial differences in immune cell infiltration in the 9L rat gliosarcoma model. Thus, the infiltration of CD4+ and CD8+ T cells as well as microglia/macrophages into glioma was substantially decreased in DcR3-producing tumors compared with control tumors. Chemotaxis assays revealed that DcR3 counteracts the chemotactic activity of CD95L against microglial cells in vitro. These findings suggest that DcR3 may be involved in the progression and immune evasion of malignant gliomas.